查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933897

按剂量、治疗方法、包装类型、通路和患者年龄分類的磷酸伯氨喹片市场，全球预测，2026-2032年

Primaquine Phosphate Tablets Market by Strength, Treatment Regimen, Packaging Type, Distribution Channel, Patient Age - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，磷酸伯氨喹片市值为 1.6839 亿美元，预计到 2026 年将成长至 1.7722 亿美元，年复合成长率为 5.84%，到 2032 年将达到 2.5056 亿美元。

主要市场统计数据
基准年 2025 1.6839亿美元
预计年份：2026年 1.7722亿美元
预测年份：2032年 2.5056亿美元
复合年增长率 (%) 5.84%

本文简要概述了影响磷酸伯氨喹片使用及相关人员决策流程的当前临床、监管和供应链趋势。

磷酸伯氨喹仍是清除休眠子、降低復发风险（尤其是在易感人群中）的重要抗疟药物。近年来，临床实践的改进、安全性监测通讯协定的更新以及分销模式的转变，正在改变医疗系统中该药物的采购和使用方式。因此，相关人员需要整合临床证据、监管要求和实际操作情况的资讯。

不断发展的临床安全通讯协定、采购重点和分销管道创新如何重塑医疗保健系统中的磷酸伯氨喹片策略

磷酸伯氨喹片市场环境正经历变革性的变化，这种变化不仅体现在临床数据上，也体现在政策、采购和分销管道的演变上。药物监测技术的进步以及对给药前安全性筛检的日益重视，提高了人们对照护现场诊断和整合式诊疗路径的期望，迫使医疗服务提供者和生产商在患者筛检和教育方面进行创新。同时，筹资策略也在进行调整，优先考虑供应的连续性，并更加重视货源多元化和紧急时应对计画，以应对地缘政治和物流方面的干扰。

评估2025年美国关税调整对磷酸伯氨喹片采购韧性、供应商策略和治疗连续性的累积影响

2025年关税上调措施正在对整个医药供应链产生明显的连锁反应，影响依赖进口原料药和成品药的采购方式和成本结构。采购团队正在透过加快供应商资质认证、寻找替代货源以及审查库存政策来应对短期价格波动和前置作业时间不确定性。这迫使製造商和经销商重新评估到岸成本、合约条款和分销网络，以确保获得所需产品并遵守不断变化的贸易规则。

深度细分洞察揭示了分销管道、剂型、患者人口统计特征、治疗方法偏好和包装形式如何影响临床应用和供应优先事项。

细分市场层面的差异对磷酸伯氨喹片的实际商业和临床决策至关重要，因为它们决定了分销重点、给药策略和患者支援需求。不同的分销管道在营运限制和接触点方面存在显着差异。医院药局环境优先考虑综合临床筛检和即时给药，线上药局管道强调简化的远距存取和病患教育，而零售药局则是慢性病依从性和社区配药的关键枢纽。了解这些分销管道的特点将有助于指导包装选择和所需材料的决策，从而支持安全用药和提高依从性。

从关键的区域观点审视监管多样性、製造地和分销挑战如何影响全球医疗保健环境中伯氨喹磷酸盐片剂的获取。

区域特征在製定伯氨喹磷酸片的政策、采购和分销策略方面发挥着至关重要的作用，每个地区都有其独特的法规结构、临床实践和物流挑战。在美洲，医疗保健生态系统往往强调整合的临床管道、以控制媒介传播疾病为目标的公共卫生项目以及影响采购週期和品质保证实践的既定监管流程。这些特征促使人们需要可靠的供应链和清晰的安全资讯沟通，以支援公共和私营部门的分销。

主要企业如何透过供应链韧性、针对性的产品设计和临床参与来保持差异化优势，从而维持伯氨喹疗法的可及性和相关人员的信心

在该治疗领域运作的公司之间的竞争动态已不再仅仅是商品价格战；它们越来越重视在品质保证、供应连续性和相关人员参与方面的差异化策略。成功的公司优先考虑健全的供应商选择框架，在整个价值链中保持透明的可追溯性，并投资于符合日益严格的药物监测要求的上市后安全性监测系统。与诊断供应商、物流供应商和区域分销商建立策略伙伴关係，正逐渐成为确保供应并同时提升对临床医生和支付方价值提案的实际有效机制。

製造商和经销商加强伯氨喹片供应韧性、临床合作和以患者为中心的商业化的可行优先事项

为保障伯氨喹磷酸片的供应并提升其价值，产业领导者应优先考虑价值链强化、临床合作和以顾客为中心的商业化这三项务实措施。首先，关键原料来源多元化并实施端到端可追溯性，将降低单一来源风险，并在出现差异时加快品质调查。同时，加强库存分析和应急合约的签订，以确保在短期供应中断的情况下仍能保持柔软性和供给能力。

我们透明的调查方法结合了相关人员访谈、监管审查和跨渠道分析，以提供可操作的见解并确定策略转折点。

本分析透过对关键相关人员的访谈、有针对性的监管审查以及对分销和临床实践趋势的系统评估，全面了解了磷酸伯氨喹片的情况。与临床医生、药品采购负责人、供应链经理和监管事务专家的对话是主要的资讯来源，为深入了解安全工作流程、配药挑战和采购重点提供了宝贵的见解。此外，本分析也系统性地回顾了与跨境药品分销相关的官方监管指南、治疗指南和贸易政策趋势，以补充上述定性观点。

总之，这项综合性综述强调了临床、监管和营运策略的综合方法，以维持和优化伯氨喹磷酸盐疗法的可及性。

确保伯氨喹磷酸片的稳定供应需要临床、商业和营运方面的协调努力。诸如安全性筛检、儿童剂量和治疗方案调整等临床要点必须透过强调多元化、文件记录和本地化适应性的供应链策略来解决。包装和剂型应根据实际配药环境进行调整，以减少给药错误并提高用药依从性。同时，企业必须优先考虑药物监测和相关人员教育，以维护其医疗服务提供者网路的信任。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 磷酸伯氨喹片市场（按剂量划分）

  • 15mg
  • 26.3mg
  • 7.5mg

9. 依治疗方法的磷酸伯氨喹片市场

  • 联合治疗
  • 单药治疗

第十章 依包装类型分類的磷酸伯氨喹片市场

  • 泡壳包装
  • 瓶子

第十一章 伯氨喹磷酸片市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依病患年龄分類的磷酸伯氨喹片市场

  • 成人
  • 儿童

第十三章 伯氨喹磷酸片市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 伯氨喹磷酸盐片剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国伯氨喹磷酸片市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国磷酸伯氨喹片市场

第十七章：中国磷酸伯氨喹片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actiza Pharmaceutical Pvt. Ltd.
  • AdvaCare Pharma
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Devlife Corporation Private Limited
  • Healthy Life Pharma Pvt. Ltd.
  • Hetero Drugs Limited
  • Intas Pharmaceuticals Limited
  • Ipca Laboratories Limited
  • Johnlee Pharmaceuticals Pvt. Ltd.
  • Lexicare Pharma Pvt. Ltd.
  • Livealth BioPharma Pvt. Ltd.
  • Lupin Limited
  • Marshall Healthcare
  • Medico Remedies Limited
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-C36616F699B0

The Primaquine Phosphate Tablets Market was valued at USD 168.39 million in 2025 and is projected to grow to USD 177.22 million in 2026, with a CAGR of 5.84%, reaching USD 250.56 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 168.39 million
Estimated Year [2026] USD 177.22 million
Forecast Year [2032] USD 250.56 million
CAGR (%) 5.84%

A concise orientation to current clinical, regulatory, and supply chain dynamics influencing primaquine phosphate tablet use and stakeholder decision pathways

Primaquine phosphate remains an essential agent within antimalarial therapy, particularly for eliminating hypnozoites and reducing relapse risk in vulnerable populations. Recent clinical practice refinements, updated safety monitoring protocols, and evolving distribution patterns have collectively changed how healthcare systems procure and deploy this therapy. Accordingly, stakeholders now require consolidated intelligence that bridges clinical evidence, regulatory expectations, and logistical realities.

This executive summary synthesizes those dimensions and articulates implications for manufacturers, distributors, clinical leaders, and procurement teams. It emphasizes practical considerations such as dosage diversification, pediatric access, and adherence to treatment regimens, while also foregrounding supply chain dependencies and regulatory compliance. The aim is to create a coherent foundation for decision-makers to prioritize interventions, mitigate operational risk, and align commercial strategies with patient-centric outcomes.

How evolving clinical safety protocols, procurement priorities, and channel innovations are reshaping strategy for primaquine phosphate tablets across healthcare systems

The landscape for primaquine phosphate tablets has experienced transformative shifts that extend beyond clinical data to encompass policy, procurement, and channel evolution. Advances in pharmacovigilance and a stronger focus on safety screening prior to administration have raised expectations for point-of-care diagnostics and integrated care pathways, pressuring providers and manufacturers to innovate in patient screening and education. Simultaneously, procurement strategies have adapted to prioritize continuity of supply, with a growing emphasis on supplier diversification and contingency planning to manage geopolitical and logistical disruptions.

Commercial models are also adapting: formulary managers and payers increasingly demand demonstrable value through improved adherence support and packaging innovations that simplify dosing for both adult and pediatric populations. Digital health platforms have begun to influence prescribing and dispensing behaviors, prompting manufacturers to consider packaging and communication strategies that better support remote dispensing and patient follow-up. Taken together, these shifts necessitate a more integrated approach to product development, distribution planning, and stakeholder engagement that aligns clinical efficacy with practical, patient-focused delivery mechanisms.

Assessing the cumulative effects of 2025 United States tariff adjustments on procurement resilience, supplier strategies, and therapeutic continuity for primaquine phosphate tablets

The introduction of increased tariff measures in 2025 has had a discernible ripple effect across pharmaceutical supply chains, influencing procurement practices and cost structures for products dependent on imported active pharmaceutical ingredients and finished doses. Procurement teams have responded by accelerating supplier qualification efforts, seeking alternative sourcing arrangements, and revising inventory policies to hedge against short-term price volatility and lead-time uncertainty. This has compelled manufacturers and distributors to reassess landed costs, contract terms, and distribution footprints to preserve access while maintaining compliance with evolving trade rules.

Clinicians and payers have felt the secondary impacts through tighter negotiation cycles and a renewed emphasis on cost containment in tender environments. In parallel, regulatory bodies and customs authorities have placed enhanced focus on documentation and origin verification, increasing administrative overhead for cross-border shipments. The cumulative effect has been heightened attention to supply-chain transparency, a shift toward regional sourcing where feasible, and a strategic recalibration of inventory buffers and contractual protections to maintain therapeutic continuity for patients reliant on primaquine phosphate therapy.

Deep segmentation insights revealing how distribution channels, dose strengths, patient age groups, regimen choices, and packaging types shape clinical use and supply priorities

Segment-level distinctions are central to practical commercial and clinical decisions for primaquine phosphate tablets because they determine distribution priorities, dosing strategies, and patient support needs. Distribution channels differ markedly in their operational constraints and touchpoints: hospital pharmacy environments prioritize integrated clinical screening and immediate administration, online pharmacy channels emphasize streamlined remote access and patient education, while retail pharmacies serve as critical points for chronic adherence and local dispensing. Understanding these channel dynamics informs decisions about packaging choices and the materials needed to support safe use and adherence.

Product strength variety directly influences prescribing behavior and inventory management. The presence of multiple strengths-including discrete low-dose and higher-dose options-permits prescribers to tailor therapy across both adult and pediatric populations and to accommodate regimen-specific titrations. Patient age segmentation underscores different safety, dosing, and counseling requirements; adult patients generally follow established dosing frameworks, whereas pediatric patients demand age- and weight-appropriate formulations and stronger caregiver education to ensure accurate administration. Treatment regimen segmentation influences clinical positioning and messaging: combination therapy necessitates coordination with partner drugs, pharmacovigilance for drug-drug interactions, and clarity on co-packaging or separate dispensing, whereas monotherapy places greater emphasis on adherence and monitoring for known safety signals. Packaging differences such as blister packs compared with bottles materially affect adherence, stability during distribution, and ease of dosing at the point of care. Blister packs can enhance dose visibility and adherence for segmented regimens, while bottles may offer economies of scale for centralized dispensing or institutional use. Collectively, these segmentation lenses guide product design, supply-chain decisions, and stakeholder communications to better align therapeutic attributes with patient and provider needs.

Critical regional perspectives on regulatory diversity, manufacturing hubs, and distribution challenges shaping access to primaquine phosphate tablets across global healthcare landscapes

Regional dynamics play a decisive role in shaping policy, procurement, and distribution approaches for primaquine phosphate tablets, with each geography presenting distinct regulatory frameworks, clinical practices, and logistical challenges. In the Americas, healthcare ecosystems often emphasize integrated clinical pathways, public health programs targeting vector-borne disease control, and established regulatory processes that influence procurement cycles and quality assurance practices. These characteristics drive demand for reliable supply chains and clear safety communication to support both public and private sector distribution.

Across Europe, the Middle East & Africa, stakeholders confront heterogenous regulatory regimes, variable healthcare infrastructure, and diverse supply-chain resilience profiles. This diversity requires adaptable strategies that span stringent regulatory compliance in some jurisdictions to capacity-building and distribution support in others, particularly where access and cold-chain stability affect rural delivery. The Asia-Pacific region combines high-volume manufacturing capacity with rapidly evolving healthcare delivery models; the region's mix of export-oriented production hubs and dynamic domestic demand necessitates close attention to quality oversight, export compliance, and packaging specifications that match local dispensing practices. Regional prioritization also affects clinical guideline adoption and the emphasis placed on pediatric access, screening protocols, and regimen integration, all of which should inform tailored distribution and stakeholder engagement plans for the therapy across jurisdictions.

How leading companies are differentiating through supply resilience, targeted product design, and clinical engagement to sustain access and stakeholder trust for primaquine therapy

Competitive dynamics among companies active in this therapeutic area increasingly emphasize differentiated approaches to quality assurance, supply continuity, and stakeholder engagement rather than commodity pricing alone. Effective companies prioritize robust supplier qualification frameworks, maintain transparent traceability across the value chain, and invest in post-market safety monitoring systems that align with heightened pharmacovigilance expectations. Strategic partnerships with diagnostic suppliers, logistics providers, and regional distributors have emerged as a practical mechanism to secure supply while enhancing the value proposition for clinicians and payers.

Product-level differentiation is achieved through packaging innovation, patient support programs, and education initiatives that reduce administration errors and support adherence across adult and pediatric populations. Companies that align product offerings with clinical workflows-by developing co-packaging options for combination regimens or by providing dosing aids for pediatric use-tend to secure stronger formulary consideration. In addition, firms that proactively engage with regulatory authorities to streamline documentation and demonstrate commitment to quality tend to experience fewer disruptions in cross-border trade and tenders. Ultimately, resilience in production, clarity in regulatory compliance, and targeted engagement with clinical stakeholders are the defining attributes of companies that successfully manage both operational risk and clinical demand.

Actionable, prioritized steps for manufacturers and distributors to strengthen supply resilience, clinical alignment, and patient-focused commercialization for primaquine tablets

Industry leaders should prioritize a pragmatic blend of supply-chain hardening, clinical alignment, and customer-centric commercialization to protect access and drive value for primaquine phosphate tablets. First, diversify supplier bases for critical inputs and implement end-to-end traceability to reduce single-source risk and expedite quality investigations when discrepancies arise. Pair this with enhanced inventory analytics and contingency contracts that provide both flexibility and capacity during near-term disruptions.

Second, synchronize product design with real-world clinical workflows by developing dosing aids, patient education materials, and packaging options that streamline use across adult and pediatric patients and that support both monotherapy and combination regimens. Third, invest in stronger pharmacovigilance and screening support tools that enable providers to implement safety protocols efficiently, reducing administrative friction and improving patient outcomes. Fourth, align commercial strategies with regional requirements by calibrating regulatory dossiers, packaging specs, and distribution models to local expectations, thereby minimizing clearance delays and improving uptake. Finally, cultivate collaborative partnerships across diagnostics, logistics, and digital-health vendors to create bundled solutions that address clinical screening, adherence monitoring, and remote dispensing, thus enhancing the product's overall value proposition to payers and providers.

A transparent research approach combining stakeholder interviews, regulatory review, and cross-channel analysis to derive practical insights and identify strategic inflection points

This analysis synthesizes primary stakeholder interviews, targeted regulatory reviews, and a structured evaluation of distribution and clinical practice trends to construct a comprehensive perspective on primaquine phosphate tablets. Primary inputs included conversations with clinicians, pharmacy procurement officers, supply-chain managers, and regulatory affairs specialists, which provided nuanced insight into safety workflows, dispensing challenges, and procurement priorities. These qualitative perspectives were complemented by systematic review of public regulatory guidance, treatment guidelines, and trade policy developments relevant to cross-border pharmaceutical movement.

Data were triangulated by comparing stakeholder statements against observed channel behaviors and supply-chain indicators to identify persistent operational themes and strategic inflection points. Particular attention was given to packaging implications for adherence, the operational distinctions across hospital, online, and retail dispensing environments, and the patient-safety implications of dosing and screening practices for adult and pediatric use. Limitations include variability in regional implementation timelines and the evolving nature of trade and regulatory policies; where applicable, recommendations emphasize flexible approaches that can be adapted as conditions change.

Concluding synthesis emphasizing integrated clinical, regulatory, and operational strategies to preserve access and optimize use of primaquine phosphate therapy

Sustaining reliable access to primaquine phosphate tablets requires coordinated action across clinical, commercial, and operational domains. Clinical imperatives such as safety screening, pediatric dosing, and regimen coordination must be matched by supply-chain strategies that emphasize diversification, documentation, and regional adaptability. Packaging and strength options should be aligned with real-world dispensing contexts to reduce dosing errors and support adherence, while companies must prioritize pharmacovigilance and stakeholder education to maintain trust across provider networks.

Taken together, the evidence underscores the importance of integrated planning: treating clinical, regulatory, and logistical factors as interdependent rather than siloed functions. Organizations that implement cross-functional governance, invest in traceable supply chains, and tailor product features to distribution realities will be better positioned to safeguard patient access and respond to policy shifts. The path forward is iterative, requiring ongoing monitoring and adaptable strategies that translate intelligence into operational measures to maintain continuity of care for patients dependent on this therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Primaquine Phosphate Tablets Market, by Strength

  • 8.1. 15 mg
  • 8.2. 26.3 mg
  • 8.3. 7.5 mg

9. Primaquine Phosphate Tablets Market, by Treatment Regimen

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Primaquine Phosphate Tablets Market, by Packaging Type

  • 10.1. Blister Pack
  • 10.2. Bottle

11. Primaquine Phosphate Tablets Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Primaquine Phosphate Tablets Market, by Patient Age

  • 12.1. Adult
  • 12.2. Pediatric

13. Primaquine Phosphate Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Primaquine Phosphate Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Primaquine Phosphate Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Primaquine Phosphate Tablets Market

17. China Primaquine Phosphate Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actiza Pharmaceutical Pvt. Ltd.
  • 18.6. AdvaCare Pharma
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Cipla Limited
  • 18.9. Devlife Corporation Private Limited
  • 18.10. Healthy Life Pharma Pvt. Ltd.
  • 18.11. Hetero Drugs Limited
  • 18.12. Intas Pharmaceuticals Limited
  • 18.13. Ipca Laboratories Limited
  • 18.14. Johnlee Pharmaceuticals Pvt. Ltd.
  • 18.15. Lexicare Pharma Pvt. Ltd.
  • 18.16. Livealth BioPharma Pvt. Ltd.
  • 18.17. Lupin Limited
  • 18.18. Marshall Healthcare
  • 18.19. Medico Remedies Limited
  • 18.20. Natco Pharma Limited
  • 18.21. Sandoz International GmbH
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Taj Pharmaceuticals Limited
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)